Dare Bioscience (DARE) Misses Q3 EPS by 55c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts DARE Hot Sheet
Join SI Premium – FREE
Dare Bioscience (NASDAQ: DARE) reported Q3 EPS of ($0.55). Revenue for the quarter came in at $41.69 million.
For earnings history and earnings-related data on Dare Bioscience (DARE) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Novo Nordisk (NVO) Tops Q3 EPS by 117c; offers outlook
- Hybe Corporation (352820:KS) PT Lowered to KRW290,000 at Goldman Sachs
- Ashland (ASH) Misses Q4 EPS by 16c ; Offers Guidance
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
